Richard Douglas Buys 70,000 Shares of Aldeyra Therapeutics (NASDAQ:ALDX) Stock

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Director Richard Douglas acquired 70,000 shares of the business’s stock in a transaction on Thursday, March 19th. The stock was acquired at an average price of $1.40 per share, for a total transaction of $98,000.00. Following the acquisition, the director owned 195,000 shares of the company’s stock, valued at approximately $273,000. This trade represents a 56.00% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Aldeyra Therapeutics Price Performance

Shares of ALDX stock traded down $0.02 during trading hours on Friday, hitting $1.81. 10,633,869 shares of the company’s stock traded hands, compared to its average volume of 5,328,849. The stock’s fifty day simple moving average is $4.78 and its two-hundred day simple moving average is $5.00. Aldeyra Therapeutics, Inc. has a 12-month low of $1.07 and a 12-month high of $6.81.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its quarterly earnings results on Friday, February 27th. The biotechnology company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.03. Equities research analysts forecast that Aldeyra Therapeutics, Inc. will post -0.92 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on ALDX shares. BTIG Research reaffirmed a “buy” rating on shares of Aldeyra Therapeutics in a research report on Tuesday. HC Wainwright restated a “neutral” rating and set a $2.00 price objective (down from $10.00) on shares of Aldeyra Therapeutics in a research note on Wednesday. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $5.50.

Aldeyra Therapeutics News Summary

Here are the key news stories impacting Aldeyra Therapeutics this week:

• Positive Sentiment: Insider buying: Director/insider Michael Alfieri increased his stake, purchasing 5,000 shares at ~$1.42 on March 18 — a modest signal of insider conviction that can be viewed as supportive amid the sell-off. SEC Filing: Insider Purchase
• Neutral Sentiment: Broker note status: HC Wainwright reaffirmed a Neutral rating and a $2.00 target while publishing updated model revisions. The Neutral stance limits upside endorsement from that shop but keeps coverage steady. HC Wainwright Reaffirms Neutral Rating
• Negative Sentiment: Analyst cuts: HC Wainwright sharply reduced EPS forecasts across 2026–2030 (Q4 2026 from $0.27 to ($0.02); FY2026 to ($0.44); FY2027 to ($0.27); FY2028–2030 also lowered). The revisions signal weaker expected profitability and push down research-driven valuation support. HC Wainwright Research Note
• Negative Sentiment: Lawsuits / investigations: Multiple law firms (Pomerantz; Levi & Korsinsky and others) have launched securities-fraud probes and class-action recruitment, alleging management misstatements around reproxalap’s efficacy and approval prospects. Litigation risk and potential disclosures raise investor uncertainty. Pomerantz Investigation Notice Levi & Korsinsky Alert
• Negative Sentiment: Market reaction / put buying: Heavy put-option activity and a multi-day slump (reports cite ~67% decline since Tuesday) indicate aggressive bearish positioning and rapid de-risking by traders following the FDA Complete Response Letter for reproxalap. That pressure has driven large volume and volatility. Put Options Flow Benzinga: What’s Going On
• Neutral Sentiment: Short-interest reports in recent feeds show inconsistent/zero values (likely data anomalies); treat reported short metrics cautiously until exchanges refresh official figures. No reliable signal from those entries.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of ALDX. Inspirion Wealth Advisors LLC bought a new position in shares of Aldeyra Therapeutics during the fourth quarter valued at $52,000. Global Retirement Partners LLC bought a new stake in shares of Aldeyra Therapeutics in the fourth quarter worth $52,000. CIBC Private Wealth Group LLC purchased a new stake in Aldeyra Therapeutics during the third quarter valued at $55,000. BNP Paribas Financial Markets lifted its holdings in Aldeyra Therapeutics by 36.9% in the third quarter. BNP Paribas Financial Markets now owns 10,610 shares of the biotechnology company’s stock valued at $55,000 after acquiring an additional 2,859 shares during the period. Finally, SG Americas Securities LLC bought a new position in Aldeyra Therapeutics in the fourth quarter valued at about $62,000. Hedge funds and other institutional investors own 59.71% of the company’s stock.

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.